Hib-DTaP-poliovirus vaccine - Baxter International

Drug Profile

Hib-DTaP-poliovirus vaccine - Baxter International

Alternative Names: Certiva-IPV-Hib; Hib-DTP-acellular-poliovirus vaccine - North American Vaccine

Latest Information Update: 18 Jan 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter International; Statens Serum Institut
  • Developer Baxter International
  • Class Haemophilus vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Diphtheria; Haemophilus infections; Pertussis; Poliomyelitis; Tetanus

Most Recent Events

  • 16 Jan 2017 Statens Serum Institut sold its vaccine production business to AJ Vaccines
  • 21 Sep 2006 Discontinued - Preclinical for Diphtheria in USA (Injection)
  • 21 Sep 2006 Discontinued - Preclinical for Haemophilus infections in USA (Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top